1,362 reports of this reaction
1.4% of all ECULIZUMAB reports
#20 most reported adverse reaction
HOSPITALISATION is the #20 most commonly reported adverse reaction for ECULIZUMAB, manufactured by Alexion Pharmaceuticals Inc.. There are 1,362 FDA adverse event reports linking ECULIZUMAB to HOSPITALISATION. This represents approximately 1.4% of all 94,110 adverse event reports for this drug.
Patients taking ECULIZUMAB who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPITALISATION is a less commonly reported adverse event for ECULIZUMAB, but still significant enough to appear in the safety profile.
In addition to hospitalisation, the following adverse reactions have been reported for ECULIZUMAB:
The following drugs have also been linked to hospitalisation in FDA adverse event reports:
HOSPITALISATION has been reported as an adverse event in 1,362 FDA reports for ECULIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPITALISATION accounts for approximately 1.4% of all adverse event reports for ECULIZUMAB, making it a notable side effect.
If you experience hospitalisation while taking ECULIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.